Akari Therapeutics (AKTX) Proxy filing summary

Executive summary

• The 2026 Annual General Meeting will be held on June 30, 2026, with 18 resolutions covering financial, governance, compensation, and capital matters.

• Shareholders and ADS holders are provided detailed instructions for voting, with proxy forms and electronic options available.

• The Board unanimously recommends voting in favor of all resolutions, emphasizing alignment with shareholder interests and company success.

Voting matters and shareholder proposals

• Resolutions include approval of statutory accounts, remuneration report and policy, re-election of six directors, auditor appointments, and executive compensation (say-on-pay).

• Additional resolutions seek approval for share issuances under Nasdaq rules, private placements, general share allotment, and disapplication of pre-emption rights.

• All resolutions except the pre-emption rights proposal require a simple majority; the special resolution requires 75% approval.

• Shareholder rights to submit proposals and call meetings are outlined, with deadlines and thresholds specified.

Board of directors and corporate governance

• The Board is divided into three classes, with Class A directors up for re-election; all nominees have extensive industry and leadership experience.

• Board committees include audit, compensation, and nominating/governance, each with independent members and formal charters.

• The Board maintains a majority of independent directors and separates the roles of Chairman and CEO.

• Shareholder communications, director nomination, and attendance policies are detailed.